SCHEMBL1788166

SCHEMBL1788166

O=C(Nc1cccc(-c2nc3ccccn3c2-c2ccnc(Nc3ccc(C4CCNC4)cc3)n2)c1)c1ccccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.60
ERBB2 P04626 5/20 0.60
IGF1R P08069 10/20 0.53
BRAF P15056 4/20 0.53
INSR P06213 5/20 0.51
MAPK14 Q16539 1/20 0.51
JAK2 O60674 1/20 0.48
LCK P06239 2/20 0.47
KDR P35968 2/20 0.47
PLK4 O00444 1/20 0.46
CHEK1 O14757 1/20 0.46
AURKA O14965 1/20 0.46
DAPK3 O43293 1/20 0.46
ROCK2 O75116 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46
CHEK2 O96017 1/20 0.46
NTRK1 P04629 1/20 0.46
PRKCG P05129 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1791575 0.96 EGFR (0.62) EGFRERBB2IGF1RBRAFINSR
SCHEMBL1790104 0.92 BRAF (0.54) EGFRERBB2IGF1RBRAFINSR
SCHEMBL1787001 0.91 IGF1R (0.58) EGFRERBB2IGF1RBRAFINSR
SCHEMBL1789318 0.91 BRAF (0.53) EGFRERBB2IGF1RBRAFINSR
SCHEMBL1789877 0.91 EGFR (0.60) EGFRERBB2IGF1RBRAFINSR
SCHEMBL1786178 0.90 EGFR (0.63) EGFRERBB2IGF1RBRAFINSR
SCHEMBL1787446 0.89 BRAF (0.58) EGFRERBB2IGF1RBRAFINSR
SCHEMBL1786276 0.89 EGFR (0.52) EGFRERBB2IGF1RBRAFINSR
SCHEMBL1787150 0.89 IGF1R (0.56) EGFRERBB2IGF1RBRAFINSR
SCHEMBL1789303 0.89 EGFR (0.61) EGFRERBB2IGF1RBRAFINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US claimed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP claimed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US claimed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO claimed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 EGFR 1013/4885ERBB2 323/4885IGF1R 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.